key: cord-0862403-44535oo8 authors: Lee, Wai Suet; Yousefi, Meisam; Yan, Biao Guo; Yong, Cythia Lingli; Ooi, Yaw Shin title: Know your enemy and know yourself – the case of SARS-CoV-2 host factors date: 2021-08-21 journal: Curr Opin Virol DOI: 10.1016/j.coviro.2021.08.007 sha: 89ca546e6edaaf15cbf674914e16395f86946f02 doc_id: 862403 cord_uid: 44535oo8 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent that causes Coronavirus Disease 2019 (COVID-19) pandemic, is a newly emerging respiratory RNA virus with exceptional transmissibility and pathogenicity. Numerous COVID-19 related studies have been fast-tracked, with the ultimate goal to end the pandemic. Here we review the major stages of SARS-CoV-2 infection cycle in cells, with specific emphasis on essential host factors. Insights into the cell biology of SARS-CoV-2 infection have accelerated the development of host-directed therapeutics, as evidenced by dozens of clinical trials evaluating COVID-19 treatments using host-targeting compounds. COVID-19 is one of the most grievous pandemics of modern human history. As of 20 months post-outbreak, SARS-CoV-2 has globally infected more than 200 million people causing over 4 million deaths (https://coronavirus.jhu.edu/map.html). A few vaccines have been authorized for emergency usage, but these efforts have yet to contain the pandemic due to limited productions and distributions [1] [2] [3] . COVID-19 research does not seem to be impacted by the stringent lockdowns and restrictions, instead, it has been conducted at an extraordinary pace to demystify the molecular biology of SARS-CoV-2 infection and pathogenesis. In this review, we summarize recently uncovered host factors critical for the various stages of the SARS-CoV-2 infection cycle ( Figure 1) . We further highlight promising druggable targets. membrane. This entry route allows the virus to access cathepsins in the endosomes, especially when TMPRSS2 is absent from the cell surface [38] . Cathepsin L (CTSL) is the principal endosomal protease responsible for priming the S protein in endosomes. It was observed that a higher level of circulating CTSL in the blood is associated with severe disease in COVID-19 patients [39] . Intriguingly, pharmacological inhibition of CTSL, but not Cathepsin B (CTSB), can reduce SARS-CoV-2 infection in vitro [8, 38] . Some other proteases such as Trypsin and Human Airway Trypsin-Like Protease (TMPRSS11D, a.k.a. HAT) have been proposed to play a similar role in the in vitro processing of the S protein [8, 27, 36] . Notably, the p41 isoform of the CD74 protein (a chaperone that regulates MHC class II antigen processing) can hinder CTSL-mediated activation of the S protein and induce resistance in human cells by arresting viral fusion inside endosomes [40] . In addition to the host proteases, SARS-CoV-2 membrane fusion in endosomes requires a low pH, as neutralization of acidic endosomes inhibits SARS-CoV-2 infection in specific cell types [7, 8, 38, 39, 41] . The impact of the endosomal pH neutralization can be reversed by overexpressing TMPRSS2, supporting the model that SARS-CoV-2 can penetrate the cellular membrane barrier either at the plasma membrane or in the endosome [7, 38] . Some host factors known to play a role in endocytosis and endosomal trafficking pathways, such as subcomponents of COMMD/CCDC22/CCDC93 Complex, Class III Phosphatidylinositol 3kinase (PI3K) Complex, RAB GTPases, and vacuolar ATPase (vATPase) complex, have been reported to promote SARS-CoV-2 infection [13, 20, [42] [43] [44] . Chemical perturbations of Two Pore Segment Channel 2 (TPCN2, a nicotinic acid adenine dinucleotide phosphate receptor), and its upstream regulator PIKFYVE, a phosphoinositide kinase that recruits protein complexes to cell-and endosomal-membrane, have been shown to potently block virus entry [8] . PIKFYVE functions can be chemically perturbed using Apilimoda candidate therapeutic for treating COVID-19 ( Table 1) . [49, 50] . Similarly, LY6E, an interferon-stimulated glycosylphosphatidylinositol-anchored protein, can block SARS-CoV-2 entry by impairing the membrane fusion regardless of the S protein maturation stages [45, 46] . IFITMs are known to block the membrane fusion of many enveloped viruses, including SARS-CoV-1 [52] . Nonetheless, IFITMs may act as double-edged swords in responding to the SARS-CoV-2 entry. IFITMs can principally inhibit SARS-CoV-2 infection, but the subcellular localization of Overall, in SARS-CoV-2 infected cells, the global host protein translation is reduced via rapid degradation of cytoplasmic mRNA and sequestration of nascent mRNA in the nucleus, allowing viral RNAs to dominate the access to ribosomes [54] . [62] [63] [64] [65] [66] [67] . In addition, the NSP1 protein can also occupy the host mRNA nuclear export complex, NXF1-NXT1, to disrupt the mRNA nuclear export [68] . Furthermore, SARS-CoV-2 ORF6 protein can alter the nuclear pore complex via interaction with Ribonucleic Acid Export 1 (RAE1) and Nucleoporin 98 (NUP98) to disrupt the bidirectional nuclear-cytoplasmic trafficking of cellular RNA [69, 70] . Additionally, SARS-CoV-2 NSP16 can interact with U1/U2 snRNA, critical components of the major spliceosome, to inhibit global pre-mRNA maturation [67] . Generally, the assembly and exit of enveloped viruses involve a cascade of irreversible events that is well-orchestrated by both viral factors and cellular components [83] . For SARS-CoV-2, the process begins when newly synthesized SARS-CoV-2 RNA genomes are exported from the DMVs via a crown-like, cylindrical membrane pore complex comprising viral proteins (e.g., NSP3) and perhaps host proteins that are yet to be identified [81, 102, 103] . This channel may also play a role in shuttling host factors and ingredients (e.g., metabolites and nucleotides) into the DMVs to fuel the viral RNA synthesis [80] . release or spread from cell to cell [80] . The formation of these protrusions involves a Casein kinase II (CK2)-dependent remodeling of the cytoskeleton that is activated by the N protein [58] . Nevertheless, the exit of viruses is not always smooth sailing; SARS-CoV-2 release from host cells can be blocked by Tetherin (BST2), an IFN-induced restriction factor targeting a broad spectrum of enveloped viruses [110, 111] . Similar to HIV-1's counteraction of Tetherin using its Vpu accessory protein [112] , SARS-CoV-2 has evolved to thwart BST2 inhibition using accessory protein ORF7a [111] . Although the spread of SARS-CoV-2 virions remains poorly understood, they are likely to transmit via both cell-free and cell-to-cell routes. Syncytia formation is commonly observed in some SARS-CoV-2 infected cells and COVID-19 patients' tissues, and it has been proposed to play a critical role in cell-to-cell transmission and pathogenesis [113] . The underlying mechanism for the syncytia formation is surprisingly similar to the TMPRSS2-dependent SARS-CoV-2 entrytriggered by the interaction between the S protein (present on the surface of donor cells) and ACE2 (on the surface of neighboring cells) [48, 114, 115] . Mechanistically, syncytia formation is regulated by a plasma membrane protein, Anoctamin 1 (ANO1, a.k.a. TMEM16), but can be restricted by IFITMs, especially IFITM1, and can be chemically intervened using Niclosamide (Table 1 ) [48, 114] . Puzzlingly, the impact of the IFITMsmediated restriction can be reversed by high levels of TMPRSS2 expression, further clouding the differences between SARS-CoV-2 entry and spread [48] . As drug discovery and approval for use entail significant resources and time, drug repurposing represents the primary line of treatment for the COVID-19 pandemic. The strategy is especially advantageous for drugs with a pre-established clinical profile and manufacturing arrangements that could expedite treatment options [116, 117] . A few SARS-CoV-2 host factors have served as promising therapeutic targets to fuel numerous preclinical screens and clinical trials ( Table 1) . Host-directed therapeutics enjoy the benefits of reduced viral resistance and their broadspectrum antiviral potential. However, selecting a suitable host target essential for a virus but dispensable for a host remains challenging. In order to avoid undesirable host responses, rigorous validation and extensive monitoring are necessary for the optimal selection of drugs and host factor candidates. J o u r n a l P r e -p r o o f Rapid multi-omics studies on SARS-CoV-2 have painted a complex picture of its infection mechanism. This molecular information is crucial for the innovation of novel antiviral strategies including new vaccine designs and host-directed antiviral therapeutics [130, 131] . It is perhaps worth noting a few caveats about these discoveries. Since the genuine SARS-CoV- In a nutshell, an unprecedented scale of coronavirus research has been rapidly conducted in response to the COVID-19 pandemic, and significant progress has been achieved to fill up knowledge gaps in some aspects of coronavirus biology. However, these findings may represent the tip of the iceberg. Humankind has witnessed the emergence of three novel coronaviruses in the past two decades, and SARS-CoV-2 is unlikely to be the last. To better prepare for the next pandemic, a comprehensive understanding of the SARS-CoV-2 biology is direly in need to stimulate the development of novel antiviral strategies, such as host-directed therapeutics that can potentially combat a broad spectrum of coronaviruses. Nothing declared. Papers of particular interest, published within the period of review, have been highlighted as: * of special interest ** of outstanding interest J o u r n a l P r e -p r o o f On the road to ending the COVID-19 pandemic: Are we there yet? Virology Viral targets for vaccines against COVID-19 Krammer F: SARS-CoV-2 vaccines in development Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses A key paper (among the firsts) to identify and characterize ACE2 as the functional receptor for SARS-CoV-2 A pneumonia outbreak associated with a new coronavirus of probable bat origin The first paper that identify SARS-CoV-2 as the etiologic agent responsible for COVID-19 Also, this is one of the first papers to demonstrate ACE2 is a functional receptor for SARS-CoV-2 A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Counter-regulatory renin-angiotensin system in cardiovascular disease Role of host factors in SARS-CoV-2 entry SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 This is the first paper to provide structural evidence showing heparan sulfate as a cellular attachment factors of SARS-CoV-2 Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses Host and viral determinants for efficient SARS-CoV-2 infection of the human lung Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks One of the key papers to study the cell biology of SARS-CoV-2 using genome-scale CRISPR screens Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2 HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection One of the key papers to study the cell biology of SARS-CoV-2 using genome-scale CRISPR screens The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells 23]) describe the multibasic cleavage site in the S1-S2 junction of SARS-CoV-2 S glycoprotein, which was absent in SARS-CoV sequence The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion Veesler D: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis These papers ([30, 31]) demonstrate the multibasic furin cleavage site is critical for SARS-CoV-2 transmission and pathogenesis Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Neuropilin-1 is a host factor for SARS-CoV-2 infection Enhancing host cell infection by SARS-CoV-2 Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses Cell entry mechanisms of SARS-CoV-2 Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells One of the key papers to study the cell biology of SARS-CoV-2 using genome-scale CRISPR screens A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors Opposing activities of IFITM proteins in SARS-CoV-2 infection Syncytia formation by SARS-CoV-2-infected cells Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2 The broad-spectrum antiviral functions of IFIT and IFITM proteins Coronavirus biology and replication: implications for SARS-CoV-2 SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis High-Resolution Analysis of Coronavirus Gene Expression by RNA Sequencing and Ribosome Profiling A SARS-CoV-2 protein interaction map reveals targets for drug repurposing The first proteome-wide study of protein-protein interactions between SARS-CoV-2 and human cells Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication The SARS-unique domain (SUD) of SARS-CoV and SARS CoV-2 interacts with human Paip1 to enhance viral RNA translation SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98 SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration Site-specific glycan analysis of the SARS-CoV-2 spike The Global Phosphorylation Landscape of SARS-CoV-2 Infection Ubiquitin-Modified Proteome of SARS-CoV-2-Infected Host Cells Reveals Insights into Virus-Host Interaction and Pathogenesis Inhibition of HECT E3 ligases as potential therapy for COVID-19 Evasion of Type I Interferon by SARS-CoV-2 SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies A molecular pore spans the double membrane of the coronavirus replication organelle Strategies for viral RNA stability: live long and prosper Viral use and subversion of membrane organization and trafficking Architecture of a SARS-CoV-2 mini replication and transcription complex Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling Discovery and functional interrogation of SARS-CoV-2 RNAhost protein interactions In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs The SARS-CoV-2 RNA interactome Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients Coronavirus interactions with the cellular autophagy machinery ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes TMEM41B is a novel regulator of autophagy and lipid mobilization Genome-wide CRISPR screen identifies TMEM41B as a gene required for autophagosome formation TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2 TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis TMEM41B and VMP1 are scramblases and regulate the distribution of cholesterol and phosphatidylserine SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication Coronavirus dons a new crown Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid The Short-and Long-Range RNA-RNA Interactome of SARS-CoV-2 Phosphoregulation of Phase Separation by the SARS-CoV-2 N Protein Suggests a Biophysical Basis for its Dual Functions The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein ER functions are exploited by viruses to support distinct stages of their life cycle β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders Counteraction of the multifunctional restriction factor tetherin Functional Landscape of SARS-CoV-2 Cellular Restriction A key paper that systematically identified host restriction factors for SARS-CoV-2 Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia A key paper investigating the mechanism of syncytia formation in SARS-CoV-2 infected cells Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2 Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing A comprehensive drug repurposing studies with validations in multiple cell lines and tissue model Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients Statin use is associated with lower disease severity in COVID-19 infection Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2 Host-directed therapies for bacterial and viral infections Bispecific antibodies for viral immunotherapy Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 This paper was the first to address why Chloroquine and its derivatives are ineffective to block SARS-CoV-2 entry in human cells and limitations in SARS-CoV-2 studies using Vero cells due to their lack of TMPRSS2 Identification of Common Deletions in the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients